Even more PACIFIC.

We know adding durvalumab following standard definitive chemoradiation for locally-advanced non-small cell lung cancer (NSCLC) improves progression-free and overall survival. This report (LBA6) details patterns of recurrence, which occur most frequently in the thorax followed by brain in both arms, though recurrences across all sites were delayed with the addition of durvalumab. | Raben, ASTRO 2019